Hepatitis C elimination: learning from Greater Manchester
| By Jeremy Hooper, James Roach, and Johnny Skillicorn-Aston
The ambition to eradicate hepatitis C must not be sidelined by COVID-19, argue Jeremy Hooper, James Roach, and Johnny Skillicorn-Aston
About the Author
Jeremy Hooper, James Roach, and Johnny Skillicorn-Aston
Jeremy Hooper Health Analyst, Conclusio Limited
James Roach (pictured) Managing Director, Conclusio Limited
Johnny Skillicorn-Aston Director of Engagement and Communications, Conclusio Limited
The approach to the elimination of disease-causing agents has undergone significant change over recent decades. The popular view of single-minded, lone scientists working in laboratories to eradicate pathogens may persist, but the reality is more nuanced.
Please sign in to continue reading this content, or...
Register for free
Access to the Specialised Medicine website is free for UK healthcare professionals and NHS managers with a role or interest in specialised healthcare and commissioning.
Sign up now–it takes less than a minute and you’ll get unlimited access to all of our independent content, including expert articles, news, views, and specialised service resources.
